Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
Life (Basel) ; 13(11)2023 Oct 28.
Article in English | MEDLINE | ID: mdl-38004270

ABSTRACT

The global aging population is expanding at an increasingly rapid pace, with approximately one-fourth of the world's population expected to be composed of elderly individuals by 2050. Aging skin is one of the major characteristics expressed in the elderly. The study comprehensively utilizes both cell and animal experiments to confirm the skin anti-aging effects of Poria cocos (P. cocos), which is one of the most important traditional Chinese medicines classified as tonic Chinese medicine, commonly used to treat physical weakness and aging-associated diseases. We demonstrate in this study that P. cocos lanostane triterpenoids extract (Lipucan®) ameliorates aging skin and promotes collagen accumulation and hyaluronic acid production in galactose-induced aging rats. Purified lanostane triterpenoids were initially identified as active components in P. cocos, which significantly increased collagen and hyaluronic acid levels in cultured human skin cells.

2.
Life (Basel) ; 11(5)2021 Apr 21.
Article in English | MEDLINE | ID: mdl-33919400

ABSTRACT

Poria cocos, called fuling, is a famous tonic in traditional Chinese medicine that reportedly possesses various pharmacological properties, including anti-inflammation and immunomodulation. However, few studies have investigated the effects of P. cocos on allergic diseases, such as allergic asthma. Allergic asthma is caused primarily by Th2 immune response and characterized by airway inflammation. This study first demonstrated the anti-allergic and anti-asthmatic effects of P. cocos extract (Lipucan®). P. cocos extract distinctly exhibited reduced inflammatory cell infiltration in the peribronchial and peribronchiolar regions compared to the asthma group in the histological analysis of pulmonary tissue sections. Prolonged P. cocos extract administration significantly reduced eosinophil infiltration, PGE2 levels, total IgE, and OVA-specific IgE. Moreover, P. cocos extract markedly suppressed Th2 cytokines, IL-4, IL-5, and IL-10. On the other hand, P. cocos extract significantly elevated IL-2 secretion by Th1 immune response. In addition, P. cocos extract elevated the IFN-γ level at a lower dose. We also observed that P. cocos extract increased the activity of NK cells. Our results suggest that P. cocos extract remodels the intrinsic Th1/Th2 response to prevent or alleviate allergy-induced asthma or symptoms.

3.
Environ Toxicol ; 36(5): 737-747, 2021 May.
Article in English | MEDLINE | ID: mdl-33325633

ABSTRACT

The overexpression of EGFR and/or ErbB2 occurs frequently in ovarian cancers and is associated with poor prognosis. The purpose of this study was to examine the anticancer effects and molecular mechanisms of berberine on human ovarian cancer cells with different levels of EGFR and/or ErbB2. We found that berberine reduced the motility and invasiveness of ovarian cancer cells. Berberine depleted both EGFR and ErbB2 in ovarian cancer cells. Furthermore, berberine suppressed the activation of the EGFR and ErbB2 downstream targets cyclin D1, MMPs, and VEGF by down-regulating the EGFR-ErbB2/PI3K/Akt signaling pathway. The berberine-mediated inhibition of MMP-2 and MMP-9 activity could be rescued by co-treatment with EGF. Finally, we demonstrated that berberine induced ErbB2 depletion through ubiquitin-mediated proteasome degradation. In conclusion, the suppressive effects of berberine on the ovarian cancer cells that differ in the expression of EGFR and ErbB2 may be mediated by the dual depletion of EGFR and/or ErbB2.


Subject(s)
Berberine , Ovarian Neoplasms , Berberine/pharmacology , Cell Line, Tumor , Down-Regulation , ErbB Receptors/genetics , ErbB Receptors/metabolism , Female , Humans , Ovarian Neoplasms/drug therapy , Phosphatidylinositol 3-Kinases/metabolism , Receptor, ErbB-2/genetics
4.
Environ Toxicol ; 36(3): 320-327, 2021 Mar.
Article in English | MEDLINE | ID: mdl-33044769

ABSTRACT

Ganoderma is one of the common medicinal mushrooms in traditional Chinese medicine. Previous researches have unveiled the multifaceted biological activity of Ganoderma extract. Ganoderma tsugae has been investigated the potential on curing prostate, colon, lung, epidermoid, breast and ovarian cancers, but not including endometrial cancer. Endometrial cancer is a gynecological malignant tumor with serious drug resistance problem in clinical cancer treatment. This study aimed to demonstrate the first study of Ganoderma on treating endometrial cancer. The Ganoderma tsugae ethanol extract (GTEE) could suppress the proliferation of endometrial cancer cells HEC-1-A, KLE, and AN3 CA. GTEE also induced G1/S phase arrest and mitochondria-mediated apoptosis in endometrial cancer cells. Furthermore, the Akt signaling pathway could be suppressed by GTEE. Therefore, our results suggest for the first time that GTEE has the potential to be an adjuvant therapeutic agent in the treatment of endometrial cancer.


Subject(s)
Drugs, Chinese Herbal/pharmacology , Endometrial Neoplasms/drug therapy , Ganoderma , Apoptosis/drug effects , Cell Line, Tumor , Cell Proliferation/drug effects , Drugs, Chinese Herbal/therapeutic use , Female , Humans , Medicine, Chinese Traditional , Proto-Oncogene Proteins c-akt/metabolism , Signal Transduction/drug effects
5.
FEBS Lett ; 592(10): 1643-1666, 2018 05.
Article in English | MEDLINE | ID: mdl-29683472

ABSTRACT

Ganoderma is classified as a top grade traditional Chinese medicine for promoting human health by regulating 'vital energy'. Its potency towards metabolism and energy homeostasis, particularly, metabolic adaptations of adipocytes, needs to be re-evaluated through an evidence-based study. Here, the triterpenoid-rich Ganoderma tsugae ethanol extract (GTEE) was found to contribute towards adipogenesis accompanied with elevated intracellular lipid metabolic flux. Additionally, proteomic profiling revealed GTEE-upregulated mitochondrial remodeling and chemical energy redox modifications, which display UCP1-positive browning fat-selective features and a NADH-mediated adaptive mechanism. GTEE-treated mice with diet-induced obesity also resulted in the amelioration of white adipocyte hypertrophy and the appearance of UCP1-positive browning adipocytes. Our novel findings unravel that GTEE could promote intracellular metabolic flexibility and plasticity followed by the induction of adipocyte browning.


Subject(s)
Adipogenesis/drug effects , Drugs, Chinese Herbal/pharmacology , Fungal Proteins/metabolism , Ganoderma/metabolism , Proteomics , 3T3-L1 Cells , Adipocytes, Brown/metabolism , Adipocytes, White/metabolism , Animals , Blotting, Western , Diet , Drugs, Chinese Herbal/chemistry , Electrophoresis, Gel, Two-Dimensional , Ethanol/chemistry , Ganoderma/chemistry , Male , Mice , NAD/metabolism , Obesity/prevention & control , Organelle Biogenesis , Oxidation-Reduction , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization , Uncoupling Protein 1/metabolism
6.
Article in English | MEDLINE | ID: mdl-23662119

ABSTRACT

Ganoderma, also known as Lingzhi or Reishi, has been used for medicinal purposes in Asian countries for centuries. It is a medicinal fungus with a variety of biological properties including immunomodulatory and antitumor activities. In this study, we investigated the molecular mechanisms by which Ganoderma tsugae (GT), one of the most common species of Ganoderma, inhibits the proliferation of HER2-overexpressing cancer cells. Here, we show that a quality assured extract of GT (GTE) inhibited the growth of HER2-overexpressing cancer cells in vitro and in vivo and enhanced the growth-inhibitory effect of antitumor drugs (e.g., taxol and cisplatin) in these cells. We also demonstrate that GTE induced cell cycle arrest by interfering with the HER2/PI3K/Akt signaling pathway. Furthermore, GTE curtailed the expression of the HER2 protein by modulating the transcriptional activity of the HER2 gene and the stability/degradation of the HER2 protein. In conclusion, this study suggests that GTE may be a useful adjuvant therapeutic agent in the treatment of cancer cells that highly express HER2.

7.
J Agric Food Chem ; 60(38): 9649-58, 2012 Sep 26.
Article in English | MEDLINE | ID: mdl-22950834

ABSTRACT

Berberine (BBR) is a natural alkaloid with significant antitumor activities against many types of cancer cells. In this study, we investigated the molecular mechanisms by which BBR repressed the metastatic potential of breast cancer cells. BBR was found to downregulate the enzymatic activities and expression levels of matrix metalloproteinases 2 and 9 (MMP2 and MMP9, respectively). The BBR-mediated suppression of MMP2 and MMP9 involved the inhibition of the Akt/nuclear factor kappa B (NF-κB) and activator protein-1 (AP-1) signaling pathways. Furthermore, BBR repressed the expression of the Akt protein by modulating the mRNA expression level and protein degradation of Akt. In conclusion, this study suggests that BBR can reduce the metastatic potential of highly metastatic breast cancer cells and may be a useful adjuvant therapeutic agent in the treatment of breast cancer by targeting the Akt pathway.


Subject(s)
Berberine/pharmacology , Breast Neoplasms/drug therapy , Breast Neoplasms/pathology , Proto-Oncogene Proteins c-akt/metabolism , Antineoplastic Agents, Phytogenic/pharmacology , Breast Neoplasms/metabolism , Cell Adhesion/drug effects , Cell Line, Tumor , Cell Movement/drug effects , Cell Survival/drug effects , Drug Screening Assays, Antitumor , Female , Humans , MCF-7 Cells/drug effects , Matrix Metalloproteinase 2/metabolism , Matrix Metalloproteinase 9/metabolism , Matrix Metalloproteinase Inhibitors/pharmacology , NF-kappa B/metabolism , Proto-Oncogene Proteins c-akt/genetics , Signal Transduction/drug effects , Transcription Factor AP-1/metabolism
8.
Article in English | MEDLINE | ID: mdl-22792123

ABSTRACT

Ganoderma tsugae (GT) is a traditional Chinese medicine that exhibits significant antitumor activities against many types of cancer. This study investigated the molecular mechanism by which GT suppresses the growth of doxorubicin-resistant lung adenocarcinoma H23/0.3 cells. Our results reveal that GT inhibits the viability of H23/0.3 cells in vitro and in vivo and sensitizes the growth suppression effect of doxorubicin on H23/0.3 cells. The data also show that GT induces S phase arrest by interfering with the protein expression of cyclin A, cyclin E, CDK2, and CDC25A. Furthermore, GT induces cellular apoptosis via induction of a mitochondria/caspase pathway. In addition, we also demonstrate that the suppression of cell proliferation by GT is through down-regulation of the PI3K/Akt signaling pathway. In conclusion, this study suggests that GT may be a useful adjuvant therapeutic agent in the treatment of lung cancer.

9.
Int J Oncol ; 39(5): 1221-31, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21720705

ABSTRACT

Oral carcinoma is a serious public health problem and the leading cause of head and neck cancer mortality worldwide. Moreover, oral cancer patients often present symptoms at a late stage and show a high recurrence rate after treatment. Therefore, there is an urgent need to identify novel biomarkers for early diagnosis or clinical oral cancer therapy. In this study, we employed a subset of lentiviral short hairpin RNAs targeted against various kinases and phosphatases, designed by The RNAi Consortium, to screen systemically and in a high-throughput manner for potential growth regulators of oral cancer cells. The screen revealed a total of 50 candidate genes, for which more than 90% of growth inhibition in human oral squamous cancer HSC-3 cells was obtained. Furthermore, bioinformatic analysis of these candidate genes identified transforming growth factor-ß receptor type II- and fms-related tyrosine kinase 3-related molecular pathways that are involved in NF-κB-mediated growth of HSC-3 cells. These candidate genes may be potential biomarkers for early diagnosis of oral cancer. In addition, these candidate genes represent potential targets for anticancer drug design helping to develop a personalized treatment to combat oral cancer.


Subject(s)
Biomarkers, Tumor/genetics , Carcinoma, Squamous Cell/genetics , Mouth Neoplasms/genetics , Phosphoric Monoester Hydrolases/genetics , Phosphotransferases/genetics , RNA, Small Interfering/genetics , Biomarkers, Tumor/metabolism , Carcinoma, Squamous Cell/enzymology , Cell Line, Tumor , Cell Proliferation , Computational Biology , Gene Expression Profiling , Gene Expression Regulation, Neoplastic , Genetic Vectors/genetics , High-Throughput Screening Assays , Humans , I-kappa B Kinase/metabolism , Lentivirus/genetics , Mouth Neoplasms/enzymology , NF-kappa B/metabolism , Phosphoric Monoester Hydrolases/metabolism , Phosphotransferases/metabolism , Protein Serine-Threonine Kinases/antagonists & inhibitors , Protein Transport , Receptor, Transforming Growth Factor-beta Type II , Receptors, Transforming Growth Factor beta/antagonists & inhibitors , Reproducibility of Results , Shc Signaling Adaptor Proteins/metabolism , Signal Transduction , Src Homology 2 Domain-Containing, Transforming Protein 1 , fms-Like Tyrosine Kinase 3/antagonists & inhibitors
10.
J Agric Food Chem ; 59(15): 8216-24, 2011 Aug 10.
Article in English | MEDLINE | ID: mdl-21699261

ABSTRACT

Berberine (BBR) is a natural alkaloid with significant antitumor activities against many types of cancer cells. This study investigated the molecular mechanisms by which BBR suppresses the growth of HER2-overexpressing breast cancer cells. The results show that BBR induces G1-phase cell cycle arrest by interfering with the expression of cyclins D1 and E and that it induces cellular apoptosis through the induction of a mitochondria/caspase pathway. The data also indicate that BBR inhibits cellular growth and promotes apoptosis by down-regulating the HER2/PI3K/Akt signaling pathway. Furthermore, it is also shown that a combination of taxol and BBR significantly slows the growth rate of HER2-overexpressing breast cancer cells. In conclusion, this study suggests that BBR could be a useful adjuvant therapeutic agent in the treatment of HER2-overexpressing breast cancer.


Subject(s)
Berberine/pharmacology , Breast Neoplasms/metabolism , Down-Regulation/drug effects , Growth Substances/pharmacology , Phosphatidylinositol 3-Kinases/metabolism , Proto-Oncogene Proteins c-akt/metabolism , Receptor, ErbB-2/genetics , Signal Transduction/drug effects , Breast Neoplasms/drug therapy , Breast Neoplasms/genetics , Cell Line, Tumor , Cell Proliferation/drug effects , Female , Gene Expression Regulation, Neoplastic/drug effects , Humans , Phosphatidylinositol 3-Kinases/genetics , Proto-Oncogene Proteins c-akt/genetics , Receptor, ErbB-2/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...